Nuevas terapias combinadas para la esclerosis múltiple

Multiple sclerosis (MS) is an inflammatory autoimmune disease characterized by demyelination and axonal loss in the central nervous system. Although new immunomodulatory therapies including interferon beta and glatiramer acetate became available during the last decade these therapies are only partially effective. There is a continuing need to develop more effective treatment strategies to combat the chronic and progressive aspects of the disease. In view of the complex pathophysiology underlying the MS disease process, combination therapy offers a rational therapeutic approach. Regardless of the treatment strategy to be employed, early intervention will remain the most important factor.